Alignment Healthcare, Inc. (ALHC) · Oct 29, 2026 · Earnings
Miss — Adjusted EPS $(0.04) vs ~$(0.039) consensus; FY26 adjusted EBITDA guide cut to $100M
Alignment Healthcare earnings show strong membership and revenue growth, but higher medical costs drove a steep cut to 2026 adjusted profit guidance.
Alignment is scaling a Medicare Advantage platform built around fast membership growth, a proprietary technology platform and a high-touch clinical model; membership had reached 294,100 by June 30, 2026. Growth is still arriving, but profitability is not keeping pace. Third-quarter revenue rose 36.7% to $1.36 billion and membership reached 301,200, up 31.2% year over year, yet adjusted EBITDA fell 32.8% to $21.8 million and the company posted an $8.1 million net loss. 〔0〕
| Metric | Q3 2026 | Q3 2025 | Consensus / prior guide |
|---|---|---|---|
| Revenue (Financial Highlights) | $1,358.3M (+36.7%) | $993.7M | ~$1,310M |
| Adjusted EPS (Income Statement) | $(0.04) | $0.02 | ~$(0.039) |
| Adjusted EBITDA (Non-GAAP reconciliation) | $21.8M (-32.8%) | $32.4M | $20M-$30M Q3 guide |
| Medical benefits ratio (Financial Highlights) | 89.5% | 87.1% | — |
| FY26 adjusted gross profit guide (Outlook) | $575M | — | $630M-$650M prior |
| FY26 adjusted EBITDA guide (Outlook) | $100M | — | $145M-$163M prior |
The central change is the medical-cost shock. Alignment says the medical benefits ratio worsened to 89.5%, reflecting higher costs in catastrophic cases and skilled nursing, plus elevated appeals and disputes; that pressure overwhelmed the operating leverage investors had been expecting from rapid scale. 〔1〕
The full-year reset is much more important than the revenue beat. Management raised 2026 membership guidance to at least 305,000 and revenue to at least $5.245 billion, above the prior $5.195-$5.225 billion range, but cut adjusted gross profit to at least $575 million from $630-$650 million and adjusted EBITDA to at least $100 million from $145-$163 million. The cuts also do not assume any benefit from corrective actions underway, leaving the near-term earnings profile materially weaker than the prior plan. 〔2〕
The balance sheet provides time to respond, not proof the problem is fixed. Cash and cash equivalents were $727.7 million at September 30, 2026, while operating cash flow was $158.4 million for the first nine months; that liquidity reduces immediate financing pressure, but the filing gives no evidence yet that medical-cost trends have turned.
Bottom line: Alignment is still winning members and producing substantial revenue growth, but the economics of that growth deteriorated sharply this quarter. The event is negative because the company had to sacrifice most of its previously expected 2026 profit in response to medical-cost pressure, even as its top-line outlook improved.
Q4 results and 2027 guidance, early 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!